<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04902144</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121550</org_study_id>
    <secondary_id>NCI-2021-04181</secondary_id>
    <secondary_id>STUDY00010137</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT04902144</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes for Offering Genetic Testing in a Tiered Approach</brief_title>
  <official_title>Breast and Ovarian Catchment Pilot Grant: Clinical Outcomes for Offering Genetic Testing in a Tiered Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial reviews and develops a clinical operations workflow to identify cancer&#xD;
      patients who meet criteria for genetic counseling and testing. This study may improve&#xD;
      utilization of genetic counseling and testing amongst community-based providers caring for&#xD;
      cancer patients in a rural and underserved area.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      PHASE I: Patients' medical data are collected.&#xD;
&#xD;
      PHASE II: Patients complete family history questionnaires and their medical data are&#xD;
      collected. Seattle Cancer Care Alliance (SCCA) subject matter experts and OMC providers&#xD;
      review patients' medical data at bi-monthly virtual conferences. OMC providers will be&#xD;
      consenting to release their patients' medical records to SCCA so that SCCA subject matter&#xD;
      experts (cancer geneticist and/or genetic counselor) can identify patients with an underlying&#xD;
      hereditary cancer syndrome to be offered genetic counseling and testing.&#xD;
&#xD;
      OMC providers receive coaching from SCCA subject matter experts for guidance on providing&#xD;
      genetic counseling and testing to their patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify cancer patients who meet criteria for genetic counseling and testing</measure>
    <time_frame>Up to study completion (Assessed up to 2 years)</time_frame>
    <description>The number of cancer patients who meet for genetic counseling and testing as identified by the study team and OMC oncology providers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uptake of genetic testing</measure>
    <time_frame>Up to study completion (Assessed up to 2 years)</time_frame>
    <description>The number of genetic testing kits ordered and processed for cancer patients who meet criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical and patient reported outcomes following genetic test results</measure>
    <time_frame>Up to study completion (Assessed up to 2 years)</time_frame>
    <description>Pertinent clinical information regarding genetic test result and related outcomes (referrals, treatment recommendations); pulled directly from EHR, genetic test reports, and patient questionnaires</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Colon Carcinoma</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Screening (medical records, coaching)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Patients' medical data are collected.&#xD;
PHASE II: Patients complete questionnaires and their medical data is collected. SCCA subject matter experts and OMC providers review patients' medical data at bi-monthly virtual conferences. OMC providers receive coaching from SCCA subject matter experts for guidance on providing genetic counseling and testing to their patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Medical data collected</description>
    <arm_group_label>Screening (medical records, coaching)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Screening (medical records, coaching)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Receive coaching</description>
    <arm_group_label>Screening (medical records, coaching)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medical oncology providers at OMC who see patients with an active diagnosis of breast,&#xD;
             ovarian, prostate, colon, or pancreatic cancer&#xD;
&#xD;
          -  Patients with an active diagnosis of breast, ovarian, prostate, colon, or pancreatic&#xD;
             cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  OMC providers who do not see patients with an active diagnosis of cancer&#xD;
&#xD;
          -  Patients who are minors&#xD;
&#xD;
          -  Patients with precancerous lesions such as ductal carcinoma in situ (the presence of&#xD;
             abnormal cells inside a milk duct in the breast) or colon polyps (a small clump of&#xD;
             cells that form on the lining of the colon or rectum)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Dubard-Gault</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Olympic Medical Cancer Center</name>
      <address>
        <city>Sequim</city>
        <state>Washington</state>
        <zip>98382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT04902144/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

